The european medicines agency (ema) has backed new treatments for es-small cell lung cancer (es-sclc), which may represent a significant change in care. Several medications, including lurbinectedin and serplulimab, have received positive opinions or are being considered for approval, although the specifics of the treatments and their intended uses are not entirely clear. The ema's committee on human medicines has recommended approval for multiple novel medications, potentially expanding treatment options for small cell lung cancer patients.